Hisamitsu Pharmaceutical : Salonpas® Named the World's No. 1 OTC Topical Analgesic Patch Brand for the Third Consecutive Year
May 17, 2019 at 02:28 am EDT
Share
Hisamitsu Pharmaceutical Co., Inc.
May 17, 2019
Salonpas® Named the World's No. 1 OTC Topical Analgesic
Patch Brand*1 for the Third Consecutive Year
Based on research by Euromonitor International (UK),*2 a leading global market research company
Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President & COO: NAKATOMI Kazuhide; hereinafter "Hisamitsu Pharmaceutical") announced that Euromonitor International Ltd. (hereinafter "Euromonitor International"), a leading international market research company, recognized "Salonpas®" as the world's No. 1 OTC topical analgesic patch brand for the third consecutive year since 2016. Euromonitor International presented Hisamitsu Pharmaceutical with two official certificates, one recognizing Salonpas®'s achievement and one naming Hisamitsu Pharmaceutical as the holder of the world's largest share in the corresponding market category for two years running.
L: The certificate recognizing Salonpas® as the world's No. 1 OTC topical analgesic patch brand
R:The certificate naming Hisamitsu Pharmaceutical as the global leader in the OTC topical analgesic patch market
*Please contact Hisamitsu Pharmaceutical (contact information below) if you would like to obtain the data for the images above.
Since its 1847 founding in the Tashiro (then Hizen-Tashiro) area of Tosu, Saga, Hisamitsu Pharmaceutical has worked to provide Japan and the rest of the world with high-quality pharmaceutical products. Always footing its operations in that local foundation and adhering to a consistent, customer-first philosophy, Hisamitsu Pharmaceutical is now in its 172nd year-a testament to a legacy that, like the recent recognition from Euromonitor International, would not have been possible without the valuable, ongoing support of the company's many customers and stakeholders.
May 18 has been registered with the Japan Anniversary Association as "Salonpas® Day," whose date has linguistic ties to the Japanese phrase "Kori o iyasu" ("relieving stiffness"): "Ko" corresponds to the number 5 ("go"); "i" represents 1; and "ya" stands for 8.
Hisamitsu Pharmaceutical will continue to expand its business operations worldwide, centering its activities on the basic principle of "Delivering a Better QOL to the World."
Certificate presentation
Date:
May 17, 2019
Location:
Hisamitsu Pharmaceutical Tokyo Head Office
L:
Mr. Sean Kreidler, Senior Research Manager, Euromonitor International
R:
NAKATOMI Kazuhide, President & COO, Hisamitsu Pharmaceutical
*1: Research Method
To determine the world's No. 1 OTC topical analgesic patch brand, London-based Euromonitor International conducts a global market research from March to April every year. In the ten countries collectively representing more than 70% of the global topical patch product retail market in 2018 (the United States, Brazil, Russia, Italy, Germany, India, Indonesia, Vietnam, China, and Japan), Euromonitor International conducted trade interviews of manufacturers and wholesalers, visited retail outlets for store checks, and compiled the sales figures of patch products by country and brand to calculate the corresponding sales shares.
*2: Euromonitor International
Euromonitor International, a British company headquartered in London, is a leader in international market research with exclusive researchers in over 100 countries.
For further information, please contact:
Public Relations Dept., Hisamitsu Pharmaceutical Co.
2-4-1 Marunouchi, Chiyoda-ku, Tokyo, Japan 100-6330
TEL: +81-3-5293-1732
Attachments
Original document
Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 17 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 17 May 2019 06:27:03 UTC
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.